RVC Deal-in-Play Virtual Investor Forum 2025

RVC Deal-in-Play Virtual Investor Forum

Virtual via Zoom

RVC Investor Forums bring together accredited angel investors interested in fast-growing, early-stage companies in Colorado. These forums serve to pool the wisdom, expertise, and capital of many individual angels. At this forum, investor members will hear pitches, and afterwards the founders are excused and investors discuss the merits and risks of each venture. There is no requirement to invest and each investor has an opportunity to indicate interest in following or leading a specific deal. Both new and experienced investor members are welcome at forums -- this is the best way to learn hands-on about angel investing! 

Meeting Agenda:

Welcome Introductions & Deal-in-Play Updates

3:00pm to 3:25 pm

Progress Updates from EnteroTrack & LumenAstra

3:25 pm to 4:15pm

Theraputech Pitch & Investor Discussion 

4:15 to 4:40pm

SpaXial Deep Dive Pitch and Investor Q&A

4:40 to 5:30pm

Presenting Companies

EnteroTrack, based in Aurora, CO, has developed the Esophageal String Test (EST) — the only non-endoscopic method to screen and monitor Eosinophilic Esophagitis (EoE), reducing patient and payer costs by over 80% compared to endoscopic biopsy. With CAP/CLIA lab operations, Medicare and major insurer reimbursements, and 50+ clinics onboarded, the company has grown test volume 10x in the past year. Backed by 5 granted and 18 pending patents, unique antibodies, and over 7 years of clinical trials, EnteroTrack is scaling toward a $4B market, seeking $2.5M to reach $3M ARR and expand its diagnostic pipeline.

LumenAstra, a Boulder-based startup, is developing a non-invasive wearable sensor that measures core body temperature below the skin, starting with real-time brain monitoring in high-risk cardiac surgeries to cut mortality by up to 20%. Backed by $3.3M in non-dilutive funding and University of Colorado patents, the company targets ICU, military, sports, and consumer markets, with FDA Class II clearance and a 2026 launch planned.

Theraputech is building a next-generation mental-health platform that blends clinical rigor with modern software and AI to help providers deliver higher-quality, more scalable care. Led by an experienced team with deep backgrounds in health systems, therapy services, and tech-enabled care delivery, the company focuses on making mental-health treatment more accessible, outcomes-driven, and operationally efficient for clinics, networks, and practitioners. With strong clinical advisory support and a product designed to meet the growing demand for effective, tech-supported mental-health solutions, Theraputech is positioned to become a foundational infrastructure player in the rapidly expanding behavioral-health market.

SpaXial is redefining how 3D developers build. With over 1 million full-time 3D professionals worldwide and more than $50B spent annually on 3D development—growing at over 20% CAGR—even a modest 20% productivity boost represents $10B+ in unlocked value. SpaXial delivers that and more. Our pilot users report 20–50% faster development cycles with our AI-powered 3D developer assistant. The timing couldn’t be better: 70% of game developers say they must “do more with less,” and generative AI is finally making that possible. While major 3D engines are introducing basic AI helpers, they aren’t solving the hardest cross-engine workflow problems that dominate real 3D development—and that’s our wedge. SpaXial’s founding team is uniquely equipped to win: I’m a Wharton-trained GTM leader who scaled a 3D applications startup to exit, and my co-founder, a PhD in AI and AR, is an early pioneer in spatial computing. We know the pain firsthand, and our early users say they “can’t imagine building without SpaXial.”

To attend this event, you must be accredited: Net worth of at least one million US dollars, not including the value of one’s primary residence, or have made at least $200,000 each year for the last two years [or $300,000 if jointly filing] and have the expectation to make the same amount this year. We do not require a minimum investment.